Boston Partners Has $191.96 Million Stock Holdings in Sanofi $SNY

Boston Partners trimmed its position in Sanofi (NASDAQ:SNY) by 2.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 3,973,860 shares of the company’s stock after selling 115,380 shares during the quarter. Boston Partners’ holdings in Sanofi were worth $191,956,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Voya Investment Management LLC increased its stake in Sanofi by 11.6% during the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock valued at $11,460,000 after purchasing an additional 21,540 shares in the last quarter. Ascent Group LLC acquired a new position in shares of Sanofi during the first quarter valued at about $426,000. 1248 Management LLC bought a new stake in shares of Sanofi during the first quarter worth about $518,000. Equity Investment Corp raised its holdings in shares of Sanofi by 2.5% in the 2nd quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock worth $121,376,000 after acquiring an additional 62,109 shares during the last quarter. Finally, Cerity Partners LLC lifted its position in Sanofi by 62.5% in the 1st quarter. Cerity Partners LLC now owns 196,726 shares of the company’s stock valued at $10,910,000 after acquiring an additional 75,698 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on SNY. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, November 5th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Stock Performance

Shares of Sanofi stock opened at $51.69 on Wednesday. The business’s fifty day simple moving average is $48.70 and its 200 day simple moving average is $49.43. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The firm has a market capitalization of $126.93 billion, a P/E ratio of 12.11, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. The firm had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue was down 7.5% compared to the same quarter last year. During the same period last year, the firm posted $2.25 EPS. As a group, analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.